Approval · Notice of Compliance 28916 · 2022
VRAYLAR: Notice of Compliance 28916
Issued September 9, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 28916
- Date
- September 9, 2022
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- Admin
- Reason
- Administrative: Merger/Buy-out
Products in this notice
Medicinal ingredients
- CARIPRAZINE HYDROCHLORIDE 1.5 MG per CAP
- CARIPRAZINE HYDROCHLORIDE 3 MG per CAP
- CARIPRAZINE HYDROCHLORIDE 4.5 MG per CAP
- CARIPRAZINE HYDROCHLORIDE 6 MG per CAP